CUA Educational Content

PSMA: From Molecular Imaging to Radioligand Therapy

SPEAKERS: FRED SAAD, ROB HAMILTON, DAVID LAIDLEY

LEARNING OBJECTIVES:

At the conclusion of this program, participants should be able to:

  • Review nuclear medicine terminology as it relates to prostate cancer and PSMA imaging and therapy
  • Review how to interpret PSMA expression and how this may help in patient selection and predict response to PSMA therapy
  • Review the present and future use of radioligand therapy in the management of advanced prostate cancer
Start Quiz for Credits

ACCREDITATION

This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Urological Association. You may claim a maximum of 1 hour of credit.

 

​This program was made possible with financial support from Advanced Accelerator Applications: A Novartis Company

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy